According to latest Symphony Health Solutions Rx data, Zubsolv tablets (4-week rolling average) show an unchanged market share of 6.07% (6.07%). The total number of Zubsolv tablets sold week 46 (45) reached 350,020 (341,754). However, Zubsolv prescriptions (TRx) were slightly lower, recording a market share (4-week rolling average) of 6.12% (6.16%), totaling 12,334 (12,449) prescriptions during the week. The overall market (buprenorphine/naloxone products) showed a y/y growth rate of 7.6% (6.7%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 6.5% (5.6%) (4-week rolling average).